KYPROLIS
KYPROLIS (Carfilzomib) is an FDA-approved proteasome inhibitor infusion therapy indicated for the treatment of multiple myeloma in adult patients. Each 1×1 EA powder vial contains 10mg, 30mg, 60mg of Carfilzomib, formulated for intravenous administration under professional supervision.
Carfilzomib works by inhibiting proteasome activity, leading to apoptosis of cancerous plasma cells and helping to control disease progression, reduce tumor burden, and improve patient outcomes. This therapy is typically used in combination with other approved medications as part of a comprehensive multiple myeloma treatment regimen.
InfusionMed USA, headquartered in Carrollton, Texas, supplies KYPROLIS and other specialty oncology infusion therapies to hospitals, clinics, and infusion centers across Dallas, McKinney, Frisco, Plano, Lewisville, The Colony, and surrounding North Texas areas. We ensure cold-chain integrity, proper handling, and timely delivery for licensed healthcare providers.
For professional use only.
Download Form